Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M82,926Revenue (TTM) $M51,309Net Margin (%)9.8Altman Z-Score1.9
Enterprise Value $M105,163EPS (TTM) $6.1Operating Margin %11.5Piotroski F-Score7
P/E(ttm)16.4Beneish M-Score-2.6Pre-tax Margin (%)12.7Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %5.8Quick Ratio1.0Cash flow > EarningsY
Price/Sales1.65-y EBITDA Growth Rate %7.6Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow14.8y-y EBITDA Growth Rate %19.6ROA % (ttm)6.0Higher Current Ratio y-yY
Dividend Yield %2.9PEG2.3ROE % (ttm)19.5Less Shares Outstanding y-yY
Payout Ratio %47.0Shares Outstanding M827ROIC % (ttm)9.7Gross Margin Increase y-yY

Gurus Latest Trades with BAYRY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAYRYKen Fisher 2016-06-30 Add0.02%$95.22 - $124.7
($108.57)
$ 100.28-8%Add 1.58%4,909,612
BAYRYKen Fisher 2016-03-31 Add0.03%$103.65 - $124.84
($111.18)
$ 100.28-10%Add 2.63%4,833,445
BAYRYKen Fisher 2015-12-31 Reduce$122.36 - $135.71
($128.61)
$ 100.28-22%Reduce -0.07%4,709,574
BAYRYKen Fisher 2015-09-30 Add0.03%$127.13 - $151.47
($139.59)
$ 100.28-28%Add 2.22%4,712,759
BAYRYKen Fisher 2015-06-30 Add0.59%$139.35 - $155
($147.22)
$ 100.28-32%Add 83.74%4,610,296
BAYRYKen Fisher 2015-03-31 Add$130.2 - $155.97
($144.95)
$ 100.28-31%Add 0.63%2,509,075
BAYRYKen Fisher 2014-06-30 Add0.6%$126.84 - $144.81
($138.38)
$ 100.28-28%Add 750.48%2,302,369
BAYRYKen Fisher 2014-03-31 Add0.06%$128.3 - $142.7
($135.49)
$ 100.28-26%Add 217.05%270,713
BAYRYKen Fisher 2013-06-30 Add0.01%$101 - $112.75
($106.88)
$ 100.28-6%Add 34.62%84,456
BAYRYVanguard Health Care Fund 2012-09-30 Reduce-0.03%$68.01 - $88.62
($77.6)
$ 100.2829%Reduce -3.71%2,594,656
BAYRYKen Fisher 2012-09-30 Buy 0.02%$68.01 - $88.62
($77.14)
$ 100.2830%New holding72,838
BAYRYKen Fisher 2012-03-31 Sold Out -0.01%$0.04 - $75.15
($59.98)
$ 100.2867%Sold Out0
BAYRYKen Fisher 2011-09-30 Add$49.73 - $84.17
($66.88)
$ 100.2850%Add 24.27%46,440
BAYRYKeeley Asset Management Corp 2009-06-30 Sold Out -0.01%$47.66 - $59.35
($52.77)
$ 100.2890%Sold Out0
BAYRYKen Fisher 2009-06-30 Sold Out $47.66 - $59.35
($52.77)
$ 100.2890%Sold Out0
BAYRYKeeley Asset Management Corp 2009-03-31 Buy 0.01%$43.75 - $59.4
($52.7)
$ 100.2890%New holding6,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAYRY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BAYRY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about BAYRY:

    News about BAYRY:

    Articles On GuruFocus.com
    Will the Monsanto-Bayer Deal Go Through? Sep 20 2016 
    Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
    Monsanto Agrees to Bayer’s Proposal Sep 15 2016 
    Monsanto: What the Gurus May Be Telling Us About a Potential Buy-Out Sep 13 2016 
    Bestinfond’s 2nd Quarter Buys Sep 13 2016 
    Causeway International Value Fund May Performance Review Jul 08 2016 
    Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
    Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
    UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
    Bayer AG Wins Approval On Existing Antibiotic For Plague Treatment May 12 2015 

    More From Other Websites
    United Therapeutics Chilled On M&A Fever Amid Actelion, Bayer Rivalry Sep 28 2016
    Monsanto ally Novozymes sees opportunity, risk in Bayer merger Sep 28 2016
    Monsanto Stock Upgraded at Goldman Sachs (MON, BAYRY) Sep 28 2016
    Monsanto ally Novozymes sees opportunity, risk in Bayer merger Sep 28 2016
    Acceleron Pharma tabs Bayer exec as next CEO Sep 27 2016
    Why Is Monsanto Still Limping? Get Ready for 4Q16 Earnings Sep 27 2016
    Monsanto Stock Upgraded at Bernstein (MON, BAYRY) Sep 27 2016
    Analysts Weigh In on Monsanto after Its Merger Announcement Sep 26 2016
    Mylan, Lupin Said to Weigh Bids for Bayer Dermatology Unit Sep 26 2016
    Profit From the M&A Wave With ETFs, Mutual Funds Sep 26 2016
    Agricultural merger mania fuels fears among small seed sellers Sep 26 2016
    New clinical guidelines: -- Iberogast™ recommended for the treatment of functional dyspepsia --... Sep 26 2016
    Monsanto (MON) Secures Tech License from Broad Institute Sep 23 2016
    Bayer at EuroTier 2016: -- Animal Health and Crop Protection from a single source -- Focus on dialog... Sep 23 2016
    New scholarships worth EUR 345,000 awarded by Bayer Foundation to promote international talents Sep 23 2016
    HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target Sep 22 2016
    Monsanto Stock Upgraded at JPMorgan (MON, BAYRY) Sep 22 2016
    Bayer Might Drop Monsanto's Toxic Name Sep 21 2016
    Bayer-Monsanto Deal Pilloried by Skeptical German Lawmakers Sep 21 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)